Skip to content

PTC Therapeutics

US · PTCT #2071 by market cap Listed 1970
56.42 -1.91 -3.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio -27.74 Cheap vs history 20th percentile
5-year average 61.04
P/E ratio -47.74 Cheap vs history 6th percentile
5-year average -9.74 · forward 33.62
P/S ratio 4.59 In line with history 64th percentile
5-year average 4.05 · forward 3.94 · #113 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
PTC Therapeutics (PTCT) 4.71B -42.42 -24.65 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value54.23 Economic moatNarrow UncertaintyHigh

Trading 3.9% above Morningstar's fair value estimate.

Fair value

PTC Therapeutics Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 17% premium over our quantitative fair value estimate of $54.23 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's lack of profitability decreases our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of 0.4% falls in the bottom 30% globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The company's lack of growth is an additional cause for concern. Stagnant revenue and earnings growth indicates a company's challenges in increasing market share and profitability. The firm's cash flow per share growth, for example, ranks in the bottom 10% compared with global peers. The pace of growth in cash flow per share has been disappointing, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

PTC Therapeutics discussion 0 comments

Add a comment